PUBLISHER: Grand View Research | PRODUCT CODE: 1790213
PUBLISHER: Grand View Research | PRODUCT CODE: 1790213
Electrophysiology Mapping And Ablation Devices Market Summary
The global electrophysiology mapping and ablation devices market size was estimated at USD 25.72 billion in 2024 and is projected to reach USD 62.61 billion by 2033, growing at a CAGR of 9.23% from 2025 to 2033. Growing adoption of electrophysiology (EP) mapping and ablation devices for the diagnosis and treatment of complex arrhythmias, particularly atrial fibrillation, is a key driver of market growth.
Rising demand for advanced rhythm management tools in both hospital and ambulatory settings, coupled with the increasing burden of cardiac conditions among younger populations due to sedentary lifestyles, smoking, and alcohol use, is accelerating device utilization. According to a February 2024 article by Johnson & Johnson Services, Inc., over 37.5 million people globally are affected by atrial fibrillation. Roughly 1 in 4 adults over 40 are projected to develop the condition during their lifetime. The increasing use of electrophysiology mapping and ablation devices for diagnosing and treating complex arrhythmias, especially atrial fibrillation, is a major growth catalyst for the market. These devices allow for highly precise localization of abnormal electrical pathways, improving procedural outcomes and reducing recurrence rates. As clinical guidelines continue to emphasize catheter ablation as a frontline therapy for symptomatic AF, adoption is gaining momentum among both high-volume centers and emerging EP programs worldwide. In March 2025, Abbott received CE Mark approval in Europe for its Volt Pulsed Field Ablation (PFA) System, enabling commercial use for atrial fibrillation treatment. The system integrates with Abbott's EnSite X mapping platform and is designed to simplify workflows using a single catheter for mapping, pacing, and ablation.
The shift toward minimally invasive cardiac procedures in both hospital and ambulatory care environments is driving demand for advanced EP mapping and ablation tools. These devices are becoming integral to rhythm management workflows, offering real-time imaging and high-resolution data. In May 2025, a joint EHRA-HRS-ESC consensus in EP Europace urged improved standardization in AI-based electrophysiology research. The EHRA AI checklist showed that fewer than 55% of studies reported essential methods, with transparency in trial registration and model training below 20%, highlighting the need for more rigorous reporting practices. The statement aims to guide future AI applications toward greater clinical reliability and reproducibility.
Global Electrophysiology Mapping And Ablation Devices Market Report Segmentation
This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. for this study, Grand View Research has segmented the global electrophysiology mapping and ablation devices market report based on procedure type, product coverage, and region: